NEVE ILAN, Israel – (COMMERCIAL THREAD) – NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox“or the”Society“), an innovative medical imaging technology company, will host a virtual tour of the Nanox.ARC at the RSNA Annual Meeting on December 1, 2021 at 11:30 a.m. EST (10:30 a.m. CST), as previously announced. Company will follow up the RSNA Virtual Tour by hosting an Investor Webinar at 2:00 PM EST on December 1. The Investor Webinar will include a replay of the RSNA Virtual Tour and will be followed by a question and answer session .

The virtual tour of Nanox.ARC in a clinical setting will be streamed from Shamir Medical Center (Assaf Harofeh), a leading public hospital in Israel with advanced diagnostic imaging capabilities. The details of the presentation are as follows:

RSNA demonstration

Wednesday December 1

11:30 a.m. EST (10:30 a.m. CST)

Interested parties can register for the RSNA Annual Meeting here https://www.rsna.org/annual-meeting

Investor webinar

Wednesday December 1

2:00 p.m. EST

Investors can access the Investor Webinar using the link that will be posted in the Investor Relations section of the Nanox website at Events & Presentations. An online question-and-answer session will follow the virtual tour.

About Nanox:

Nanox, founded by serial entrepreneur Ran Poliakine, is an Israeli company developing a commercial grade digital x-ray source designed for use in real medical imaging applications. Nanox believes its new technology could dramatically reduce the costs of medical imaging systems and plans to seek collaborations with leading healthcare organizations and companies to provide affordable early detection imaging services for all. . For more information, please visit www.nanox.vision.

Forward-looking statements:

This press release may contain forward-looking statements subject to risks and uncertainties. All statements that are not historical facts contained in this press release are forward-looking statements. Such statements include, without limitation, any statement relating to the initiation, timing, advancement and results of the Company’s research and development, manufacturing and marketing activities with respect to its source technology. of X-rays and the Nanox.ARC, the ability to realize the expected benefits of acquisitions and the projected business prospects of the Company and the acquired companies. In some cases, you can identify forward-looking statements by words such as “may”, “could”, “believe”, “could”, “estimate”, “continue”, “anticipate”, “intend”, “Should,” “” “” ” ” Forward-looking statements are based on information available to the Company at the time such statements are made or on the good faith belief of management at that time as to concerns future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed or suggested by forward-looking statements. Factors that could cause actual results to differ materially from those currently anticipated include: risks related to (1) the inability to successfully integrate the businesses of the acquired companies, (2) the inability to realize the benefits expected from acquisitions, which may be affected by, among others, competition, brand recognition, the ability of acquired companies to grow and manage growth profitably and retain key employees, (3) related costs unknown or invaluable acquisitions and / or liabilities, (4) changes in applicable laws or regulations that impact the operations of acquired companies, (5) failure to meet projected technology development goals, (6) ) the inability of acquired companies to effectively scale end-to-end medical imaging solutions around the world, (7) changes in global forces, political, economic, commercial, competitive, market and regulatory, and (8) (i) Nanox’s ability to complete the development of Nanox.Arc; (ii) Nanox’s ability to successfully demonstrate the feasibility of its technology for commercial applications; (iii) Nanox’s expectations regarding the need, timing, receipt and maintenance of regulatory authorizations or approvals regarding its X-ray source technology and the Nanox. Arc from regulatory agencies around the world and its continued compliance applicable quality standards and regulatory requirements; (iv) Nanox’s ability to enter into and maintain commercially reasonable agreements with third party manufacturers and suppliers to manufacture the Nanox.Arc; (v) market acceptance of the Nanox.Arc and the proposed pay per read business model; (vi) Nanox’s expectations regarding collaborations with third parties and their potential benefits; and (vii) Nanox’s ability to conduct business on a global basis, among others.

For a discussion of other risks and uncertainties, and other important factors, each of which could cause Nanox’s actual results to differ from those contained in forward-looking statements, see the section entitled “Risk Factors” in Nanox’s Annual Report. on Form 20-F for the year ended December 31, 2020 and subsequent filings with the United States Securities and Exchange Commission. The reader should not place undue reliance on the forward-looking statements included in this press release.

Except as required by law, Nanox does not undertake to publicly update any forward-looking statements after the date of this report to conform such statements to actual results or to changes in the Company’s expectations.